1282041-92-2Relevant academic research and scientific papers
ANTIMALARIAL AGENTS THAT ARE INHIBITORS OF DIHYDROOROTATE DEHYDROGENASE
-
, (2011/04/25)
Inhibitors of parasitic dihydroorotate dehydrogenase enzyme (DHOD) are candidate therapeutics for treating malaria. Illustrative of such therapeutic agents include the compound: and a triazolopyrimidine class of compounds that conform to Formula (IX): and their solvates, stereoisomers, tautomers and pharmaceutically acceptable salts.
Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential
Coteron, Jose M.,Marco, María,Esquivias, Jorge,Deng, Xiaoyi,White, Karen L.,White, John,Koltun, Maria,El Mazouni, Farah,Kokkonda, Sreekanth,Katneni, Kasiram,Bhamidipati, Ravi,Shackleford, David M.,Angulo-Barturen, I?igo,Ferrer, Santiago B.,Jiménez-Díaz, María Belén,Gamo, Francisco-Javier,Goldsmith, Elizabeth J.,Charman, William N.,Bathurst, Ian,Floyd, David,Matthews, David,Burrows, Jeremy N.,Rathod, Pradipsinh K.,Charman, Susan A.,Phillips, Margaret A.
, p. 5540 - 5561 (2011/10/03)
Drug therapy is the mainstay of antimalarial therapy, yet current drugs are threatened by the development of resistance. In an effort to identify new potential antimalarials, we have undertaken a lead optimization program around our previously identified triazolopyrimidine-based series of Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors. The X-ray structure of PfDHODH was used to inform the medicinal chemistry program allowing the identification of a potent and selective inhibitor (DSM265) that acts through DHODH inhibition to kill both sensitive and drug resistant strains of the parasite. This compound has similar potency to chloroquine in the humanized SCID mouse P. falciparum model, can be synthesized by a simple route, and rodent pharmacokinetic studies demonstrated it has excellent oral bioavailability, a long half-life and low clearance. These studies have identified the first candidate in the triazolopyrimidine series to meet previously established progression criteria for efficacy and ADME properties, justifying further development of this compound toward clinical candidate status.
